Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286780/
https://www.ncbi.nlm.nih.gov/pubmed/34285523
http://dx.doi.org/10.2147/CEOR.S328284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286780/
https://www.ncbi.nlm.nih.gov/pubmed/34285523
http://dx.doi.org/10.2147/CEOR.S328284

Ejemplares similares